[go: up one dir, main page]

NO20080820L - Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid - Google Patents

Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid

Info

Publication number
NO20080820L
NO20080820L NO20080820A NO20080820A NO20080820L NO 20080820 L NO20080820 L NO 20080820L NO 20080820 A NO20080820 A NO 20080820A NO 20080820 A NO20080820 A NO 20080820A NO 20080820 L NO20080820 L NO 20080820L
Authority
NO
Norway
Prior art keywords
methylimidazol
ylamino
trifluoromethylphenyl
pyridin
methyl
Prior art date
Application number
NO20080820A
Other languages
English (en)
Other versions
NO341930B1 (no
Inventor
Paul Allen Sutton
Wen-Chung Shieh
Paul Manley
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Jorg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080820(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20080820L publication Critical patent/NO20080820L/no
Publication of NO341930B1 publication Critical patent/NO341930B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Krystallinske former av 4-metyl-N-[3-(4-metylimidazol-l-yl)-5-trifluormetylfenyl]-3(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamid fri base og salter derav er fremstilt ved forskjellige fremgangsmåter.
NO20080820A 2005-07-20 2008-02-14 Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid NO341930B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
PCT/US2006/027875 WO2007015870A2 (en) 2005-07-20 2006-07-18 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (2)

Publication Number Publication Date
NO20080820L true NO20080820L (no) 2008-04-15
NO341930B1 NO341930B1 (no) 2018-02-19

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080820A NO341930B1 (no) 2005-07-20 2008-02-14 Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid

Country Status (42)

Country Link
US (4) US8343984B2 (no)
EP (5) EP2284168A3 (no)
JP (3) JP5289948B2 (no)
KR (3) KR20130085444A (no)
CN (2) CN103804356A (no)
AR (1) AR054846A1 (no)
AU (3) AU2006276204A1 (no)
BR (1) BRPI0613615B1 (no)
CA (1) CA2614334C (no)
CR (1) CR9657A (no)
CU (1) CU23916B1 (no)
CY (2) CY1113076T1 (no)
DK (2) DK2284167T4 (no)
EA (2) EA013464B1 (no)
EC (1) ECSP088119A (no)
ES (3) ES2623608T5 (no)
GE (1) GEP20115302B (no)
GT (1) GT200600315A (no)
HN (1) HN2008000311A (no)
HR (2) HRP20120573T1 (no)
HU (1) HUE031791T2 (no)
IL (2) IL188189A0 (no)
JO (1) JO3308B1 (no)
LT (1) LT2284167T (no)
MA (1) MA29626B1 (no)
MX (1) MX2008000899A (no)
MY (1) MY148554A (no)
NI (1) NI200800017A (no)
NO (1) NO341930B1 (no)
NZ (1) NZ564409A (no)
PE (1) PE20070214A1 (no)
PH (1) PH12013501590A1 (no)
PL (2) PL2284167T5 (no)
PT (2) PT2284167T (no)
RS (1) RS55929B2 (no)
SG (1) SG163620A1 (no)
SI (2) SI1912973T1 (no)
SM (1) SMAP200800011A (no)
TN (1) TNSN08029A1 (no)
TW (1) TWI406661B (no)
UA (1) UA94234C2 (no)
WO (1) WO2007015870A2 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CA2644841C (en) * 2006-04-07 2013-07-16 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
PT2240172E (pt) * 2007-12-21 2014-05-28 Novartis Ag Combinação de nilotinib e clorambucilo para o tratamento da leucemia linfocítica crónica
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
ES2394258T3 (es) 2008-11-05 2013-01-30 Teva Pharmaceutical Industries Ltd. Formas cristalinas de Nilotinib HCL
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
RU2011140404A (ru) 2009-03-06 2013-04-20 Новартис Аг Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
MX2012004709A (es) 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (no) * 2010-01-15 2016-09-02
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
US8937082B2 (en) 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
PH12014500897A1 (en) 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
AR088844A1 (es) 2011-11-14 2014-07-10 Novartis Ag Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
EP2626355B1 (en) * 2012-02-09 2016-02-03 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
EP2906554A4 (en) * 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
SI3431475T1 (sl) * 2013-02-21 2021-08-31 Pfizer Inc. Trdne oblike selektivnega zaviralca CDK4/6
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CA2912902A1 (en) * 2013-04-24 2014-10-30 Dr. Reddy's Laboratories Limited Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
EP3177610A4 (en) 2014-08-08 2018-01-10 Dr. Reddy's Laboratories Ltd. Process for the preparation of polymorphic forms of nilotinib
US10016423B2 (en) * 2014-10-16 2018-07-10 Apotex Inc. Solid forms of nilotinib hydrochloride
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
RS60939B1 (sr) 2016-03-14 2020-11-30 Pliva Hrvatska D O O Čvrsti oblici soli nilotiniba
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN112423757A (zh) * 2018-06-15 2021-02-26 汉达生技医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
CA3224750A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
CN113788817A (zh) * 2021-09-27 2021-12-14 南京海润医药有限公司 一种尼罗替尼半盐酸盐一水合物晶型及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
KR101153647B1 (ko) * 2003-11-18 2012-06-18 노파르티스 아게 Ｋｉｔ 돌연변이형에 대한 저해제
GT200600316A (es) † 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Also Published As

Publication number Publication date
HN2008000311A (es) 2011-01-24
JP2014221831A (ja) 2014-11-27
AU2012201453B2 (en) 2013-09-05
US8343984B2 (en) 2013-01-01
JP2009502795A (ja) 2009-01-29
US20130023548A1 (en) 2013-01-24
UA94234C2 (uk) 2011-04-26
CU23916B1 (es) 2013-07-31
PL2284167T3 (pl) 2017-07-31
TW200740793A (en) 2007-11-01
CR9657A (es) 2008-04-16
KR101651288B1 (ko) 2016-08-25
EA200800201A1 (ru) 2008-06-30
PL1912973T3 (pl) 2012-09-28
JP2013018789A (ja) 2013-01-31
WO2007015870A3 (en) 2007-06-07
PH12013501590A1 (en) 2015-09-21
MA29626B1 (fr) 2008-07-01
US20140343087A1 (en) 2014-11-20
CY1119624T1 (el) 2018-04-04
EA201000145A1 (ru) 2010-06-30
EP2284167B2 (en) 2019-11-27
HRP20170634T4 (hr) 2020-02-07
TWI406661B (zh) 2013-09-01
DK1912973T3 (da) 2012-07-23
GEP20115302B (en) 2011-10-10
JP5798101B2 (ja) 2015-10-21
NZ564409A (en) 2011-07-29
PT2284167T (pt) 2017-05-15
GT200600315A (es) 2007-03-19
SI2284167T1 (sl) 2017-05-31
BRPI0613615B1 (pt) 2022-02-08
PL2284167T5 (pl) 2020-07-27
CA2614334C (en) 2015-04-21
ES2386974T3 (es) 2012-09-10
MY148554A (en) 2013-04-30
ES2623608T5 (es) 2020-06-18
NI200800017A (es) 2009-03-03
EP2284167A3 (en) 2011-03-02
RS55929B1 (sr) 2017-09-29
MX2008000899A (es) 2008-03-18
WO2007015870A2 (en) 2007-02-08
US8829015B2 (en) 2014-09-09
EP1912973A2 (en) 2008-04-23
EP2284167A2 (en) 2011-02-16
IL188189A0 (en) 2008-03-20
JO3308B1 (ar) 2018-09-16
JP5289948B2 (ja) 2013-09-11
SI1912973T1 (sl) 2012-08-31
SMP200800011B (it) 2008-02-27
TNSN08029A1 (en) 2009-07-14
US8415363B2 (en) 2013-04-09
PT1912973E (pt) 2012-09-03
CY1113076T1 (el) 2016-04-13
AU2006276204A1 (en) 2007-02-08
AU2012201453A1 (en) 2012-04-05
NO341930B1 (no) 2018-02-19
AR054846A1 (es) 2007-07-18
BRPI0613615A2 (pt) 2011-01-18
SG163620A1 (en) 2010-08-30
SI2284167T2 (sl) 2020-03-31
CA2614334A1 (en) 2007-02-08
EP2543665A3 (en) 2013-05-29
PE20070214A1 (es) 2007-04-02
AU2011202047A1 (en) 2011-05-26
IL214659A0 (en) 2011-09-27
KR20130085444A (ko) 2013-07-29
EP2284167B1 (en) 2017-02-01
HUE031791T2 (en) 2017-08-28
EP2535337B1 (en) 2017-08-23
EP2284168A3 (en) 2011-04-13
EP2284168A2 (en) 2011-02-16
HRP20120573T1 (hr) 2012-08-31
ES2623608T3 (es) 2017-07-11
KR20080027853A (ko) 2008-03-28
RS55929B2 (sr) 2020-12-31
US20080269269A1 (en) 2008-10-30
DK2284167T3 (en) 2017-05-01
LT2284167T (lt) 2017-04-25
DK2284167T4 (da) 2020-03-02
EP2543665A2 (en) 2013-01-09
CN102358736A (zh) 2012-02-22
US20130165465A1 (en) 2013-06-27
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
EA016856B1 (ru) 2012-08-30
KR20130077915A (ko) 2013-07-09
HRP20170634T1 (hr) 2017-06-30
SMAP200800011A (it) 2008-02-27
CU20080006A7 (es) 2011-02-24
ECSP088119A (es) 2008-02-20
ES2648288T3 (es) 2017-12-29
EP1912973B1 (en) 2012-06-13
EA013464B1 (ru) 2010-04-30
EP2535337A1 (en) 2012-12-19
HK1116783A1 (en) 2009-01-02

Similar Documents

Publication Publication Date Title
NO20080820L (no) Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
NO20080897L (no) Salter av 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
NO20071843L (no) Substituerte anilinderivater
NO20084307L (no) Heterocykliske GPCR agonister
PE20110810A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
ATE523507T1 (de) Piperidin-gpcr-agonisten
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20080051L (no) Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20072005L (no) Nye heterocykliske amider
UY29369A1 (es) Nueva sal de 1-(-3-(3-(4-clorofenil) propoxi(propil) -piperidina
NO20082118L (no) Heterocykliske CETP-inhibitorer
DK2035375T3 (da) 1,3 Disubstituerede 4-methyl-1H pyrrol-2-carboxamider og deres anvendelse til fremstilling af lægemidler
MX2008001538A (es) Aril piridinas y metodos para su uso.
DK1912954T3 (da) Hidtil ukendte cysteinproteaseinhibitorer og deres terapeutiske applikationer
NO20064410L (no) Fremgangsmate for fremstilling av tryptaseinhibitorer
NO20082412L (no) Kinaseinhibitorer